Ann: Investor Webinar, page-3

From an interview apparently with Phil Cawood from Alpine from ----head:

And LTP has a lot happening quickly after listing, including:

• A Bioequivalence Trial, scheduled to commence first quarter 2024 (~late February).
• First patient enrolments.
• First patient dosing.
• Last patient dosing.
• Trial results. The trial only takes five days, however, those results should be known sometime in April or May.
• And then, an announcement of the first sales will be made. They’re planning for first sales under special access in Australia in the second quarter of 2024 (based on trial results).

One other coment I like:

Also, LTP does not require a lot of money – hence the small raise – and the commercial upside is huge once approved.